Efficacy of acellular pertussis vaccine in early childhood after household exposure

JAMA

Volumn 275, Issue 1, 1996, Pages 37-41

  Schmitt, Heinz J ^a,i   Von König, Carl H Wirsing ^b   Neiss, Albrecht ^c   Bogaerts, Hugues ^d   Bock, Hans L ^d   Schulte Wissermann, Hermann ^b   Gahr, Manfred ^e   Schult, Rainer ^f   Folkens, Jens U ^g   Rauh, Wolfgang ^h   Clemens, Ralf ^d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b HELIOS KLINIKUM KREFELD   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f Pediatricians of Flensburg   (Germany)

^g Children's Hospital Orfenburg   (Germany)

^h Mutterhaus der Borromaerinnen   (Germany)

ⁱ UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

ARTICLE; CONTACT EXAMINATION; DRUG EFFICACY; GERMANY; HOUSEHOLD; HUMAN; PERTUSSIS; PRIORITY JOURNAL; PROPHYLAXIS; VACCINATION;

EID: 13344295089     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.1.37     Document Type: Article

References (22)

1. Edwards KM, Meade BD, Decker MD, et al. Comparison of thirteen acellular pertussis vaccines: serologic response. Pediatr Res. 1995;96:548-557.
2. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of thirteen acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96:557-566.
3. Kimura M, Kuno-Sakai H. Pertussis vaccines in Japan. Acta Paediatr Jpn. 1988;30:143-153.
4. Mortimer EA, Kimura M, Cherry JD, et al. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. AJDC. 1990;144:899-904.
5. Aoyama T, Murase Y, Kato T, Iwata T. Efficacy of an acellular pertussis vaccine in Japan. J Pediatr. 1985;107:80-83.
6. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet. 1988;1:955-960.
7. Storsaeter J, Blackwelder WC, Hallander HO. Pertussis antibodies, protection, and vaccine efficacy after household exposure. AJDC. 1992;146:167-172.
8. Schmitz M, Wassilak SGF, Schulte-Wissermann H, Wirsing von Konig CH. Schatzung zur Pertussisinzidenz am linken Niederrhein. Monatsschrift Kinderkeilkunde. 1994;142:41-44.
9. WHO Meeting on Case Definition of Pertussis: Geneva, 10-11 January 1991. Geneva, Switzerland; 1991:4-5. Document MIN/EPI/PERT/91.1.
10. Burstyn DG, Baraff LJ, Peppler MS, Leake RD, St. Gerne J Jr, Manclark CR. Serologic response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun. 1983;41:1150-1156.
11. Marwick C. Acellular pertussis vaccine hailed for infants. JAMA. 1995;274:446-147.
12. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med. 1995;333:1045-1050.
13. O'Neill RT. On sample sizes to estimate the protective efficacy of a vaccine. Stat Med. 1988;7:1279-1288.
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
15. Pocock SJ. Clinical Trials: A Practical Approach. New York, NY: John Wiley & Sons; 1983.
16. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63:1055-1068.
17. Muller AS. Pertussis: Epidemiology and Control. Geneva, Switzerland: World Health Organization; 1984, Document EPI/GAG/84/WP.11.1984.
18. Sprauer MA, Cochi SL, Zell ER, et al. Prevention of secondary transmission of pertussis in households with early use of erythromycin. AJDC. 1992;46:177-181.
19. Mertsola J, Ruuskanen O, Eskola E, Viljanen MK, Interfamilial spread of pertussis. J Pediatr. 1983;103:359-363.
20. Broome CV, Preblud SR, Bruner B, et al. Epidemiology of pertussis. Atlanta, 1977. Pediatrics. 1981;98:362-367.
21. Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis. 1987;9:866-883.
22. Storsaeter J, Olin P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine. 1992;10:142-144.